Entrada Therapeutics, Inc.
TRDA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $240 | $278 | $371 | $706 |
| - Cash | $93 | $72 | $68 | $101 |
| + Debt | $52 | $55 | $57 | $59 |
| Enterprise Value | $200 | $260 | $360 | $664 |
| Revenue | $2 | $2 | $21 | $37 |
| % Growth | -17.2% | -90.5% | -45% | – |
| Gross Profit | -$37 | $2 | $21 | $37 |
| % Margin | -2,276.8% | 100% | 100% | 100% |
| EBITDA | -$42 | -$46 | -$21 | -$5 |
| % Margin | -2,617.7% | -2,349.5% | -101.4% | -13% |
| Net Income | -$44 | -$43 | -$17 | $1 |
| % Margin | -2,734.4% | -2,210.4% | -84.4% | 3% |
| EPS Diluted | -1.06 | -1.04 | -0.42 | 0.026 |
| % Growth | -1.9% | -147.6% | -1,697% | – |
| Operating Cash Flow | -$28 | -$29 | -$39 | -$32 |
| Capital Expenditures | $0 | -$0 | -$1 | -$1 |
| Free Cash Flow | -$28 | -$30 | -$40 | -$32 |